Literature DB >> 10464211

Regulation of cell component production by growth rate in the group B Streptococcus.

R A Ross1, L C Madoff, L C Paoletti.   

Abstract

Group B Streptococcus (GBS) is the leading cause of bacterial sepsis and meningitis among neonates. While the capsular polysaccharide (CPS) is an important virulence factor of GBS, other cell surface components, such as C proteins, may also play a role in GBS disease. CPS production by GBS type III strain M781 was greater when cells were held at a fast (1.4-h mass-doubling time [td]) than at a slow (11-h td) rate of growth. To further investigate growth rate regulation of CPS production and to investigate production of other cell components, different serotypes and strains of GBS were grown in continuous culture in a semidefined and a complex medium. Samples were obtained after at least five generations at the selected growth rate. Cells and cell-free supernatants were processed immediately, and results from all assays were normalized for cell dry weight. All serotypes (Ia, Ib, and III) and strains (one or two strains per serotype) tested produced at least 3.6-fold more CPS at a td of 1. 4 h than at a td of 11 h. Production of beta C protein by GBS type Ia strain A909 and type Ib strain H36B was also shown to increase at least 5.5-fold with increased growth rate (production at a td of 1. 4 h versus 11 h). The production of alpha C protein by the same strains did not significantly change with increased growth rate. The effect of growth rate on other cell components was also investigated. Production of group B antigen did not change with growth rate, while alkaline phosphatase decreased with increased growth rate. Both CAMP factor and beta-hemolysin production increased fourfold with increased growth rate. Growth rate regulation is specific for select cell components in GBS, including beta C protein, alkaline phosphatase, beta-hemolysin, and CPS production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464211      PMCID: PMC94046     

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  32 in total

1.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus.

Authors:  H J Jennings; K G Rosell; E Katzenellenbogen; D L Kasper
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

3.  Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus.

Authors:  H J Jennings; E Katzenellenbogen; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

4.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide.

Authors:  M R Wessels; J L DiFabio; V J Benedì; D L Kasper; F Michon; J R Brisson; J Jelínková; H J Jennings
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

6.  Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine.

Authors:  M B Marques; D L Kasper; A Shroff; F Michon; H J Jennings; M R Wessels
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Type-specific antigens of group B type Ic streptococci.

Authors:  H W Wilkinson; R G Eagon
Journal:  Infect Immun       Date:  1971-11       Impact factor: 3.441

8.  Group B beta-hemolytic streptococci and puerperal infections.

Authors:  S Faro
Journal:  Am J Obstet Gynecol       Date:  1981-03-15       Impact factor: 8.661

9.  Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.

Authors:  L C Paoletti; R A Ross; K D Johnson
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

10.  Lethal effect of CAMP-factor and UBERIS-factor--a new finding about diffusible exosubstances of streptococcus agalactiae and Streptococcus uberis.

Authors:  B Skalka; J Smola
Journal:  Zentralbl Bakteriol A       Date:  1981
View more
  6 in total

1.  MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo.

Authors:  Daniel Shelver; Lakshmi Rajagopal; Theresa O Harris; Craig E Rubens
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

2.  Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in Streptococcus agalactiae.

Authors:  Lakshmi Rajagopal; Anthony Vo; Aurelio Silvestroni; Craig E Rubens
Journal:  Mol Microbiol       Date:  2006-09-27       Impact factor: 3.501

3.  Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by group B Streptococcus.

Authors:  G Malin; L C Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

4.  Molecular analysis of the Enterococcus faecalis serotype 2 polysaccharide determinant.

Authors:  Lynn E Hancock; Brett D Shepard; Michael S Gilmore
Journal:  J Bacteriol       Date:  2003-08       Impact factor: 3.490

Review 5.  Understanding the regulation of Group B Streptococcal virulence factors.

Authors:  Lakshmi Rajagopal
Journal:  Future Microbiol       Date:  2009-03       Impact factor: 3.165

6.  Bacterial phenotype variants in group B streptococcal toxic shock syndrome.

Authors:  Parham Sendi; Linda Johansson; Samira Dahesh; Nina M Van-Sorge; Jessica Darenberg; Mari Norgren; Jan Sjölin; Victor Nizet; Anna Norrby-Teglund
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.